Health Trials

Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates

ConditionsPharmacokineticsLiposomal Amphotericin BCritically Ill Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.

Eligibility criteria

Qualifiers

Treatment with L-AmB

Admitted to an ICU or Hematology ward

Disqualifiers

DNR 2 or 3

Pregnant or lactating women

Previous documentation of intolerance/sensitivity to L-AmB

Trial design

Treatments tested in this trial

  • Sample collection

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

KU Leuven

Collaborator

Source ClinicalTrials.gov